Sign in to view content

PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration

David T.W. Wong, MD, FRCS(C), FASRS

Video
Published 2025

Related

Fas Inhibition With ONL1204 for the Treatment of Geographic Atrophy: First-Time Results From a Phase 1b Study
Durga Borkar, MD
Annual Meeting Talks
2024
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.
Michael Peter Fielden, MD, FRCS(C)
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more